GLP-Complete: 3-Step System for Natural GLP-1 Pathway Support & Metabolic Balance
3-step daily system supporting GLP-1, gut health, and metabolism. · $119.99 or $101.99/mo
BLOG / Health & Wellness Library
/ Why L-Theanine Feels Like It Stops Working for Overstimulated Executives (And What Three-Point Glutamate-GABA Support Is Designed to Address)
A meta-analysis of 31 randomized trials and a triple-blind trial at the exact dose in the capsule give high-performing professionals something concrete to evaluate, including the parts most supplement marketing leaves out.
Every supplement protocol guide tells executives to add L-theanine to their morning routine. If you have tried it, you probably recognize what happens next. A stretch of noticeably smoother focus. Then a quiet slide back to baseline restlessness and the same scattered head you were trying to get out of. By mid-afternoon you have decided the research was oversold, or your brain chemistry is somehow different, or supplements just don’t do what clinical trials say they do.
Here is what the research actually shows. In the dedicated human pharmacokinetic study (van der Pijl et al., 2010), plasma L-theanine peaked roughly 50 minutes after an oral dose and fell with an elimination half-life of about an hour, so levels start declining from around the one-hour mark and are largely cleared within about five hours. The measured brainwave difference in the trial on our ingredient source was observed at three hours. That is pharmacokinetics. It isn’t personal failure.
For overstimulated executives dealing with afternoon slumps, daily tension, and a mind that is still running at bedtime, L-Theanine Pro is a neuro-cofactor formulation built around three points on the glutamate-GABA pathway rather than one piece of it. In a meta-analysis of 31 randomized controlled trials involving 1,168 participants in total, the subset of trials using a single 200 mg dose taken 30 to 60 minutes before cognitive testing showed significantly improved choice reaction time (SMD 0.51, 95% CI 0.25–0.77), and the authors concluded that L-theanine is safe and shows a robust short-term benefit on attention in healthy adults. That is the exact dose in one capsule.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
That’s the evidence. Now here is what it does and doesn’t support.
What Should You Look For in a Supplement for Calm Focus?
Look for a disclosed, dose-matched amount of L-theanine, a magnesium form selected for central nervous system delivery, and the active coenzyme form of vitamin B6 — with the evidence for each stated plainly rather than pooled into a proprietary blend. L-Theanine Pro combines all three in a single daily capsule and is formulated to support a calm, focused mental state through demanding workdays.*
Here is the evidence behind each part. Neuro-Cofactor Technology™ is built around three points on the glutamate-GABA pathway: L-theanine is a structural analogue of glutamate that crosses the blood-brain barrier via the leucine-preferring transport system (Yokogoshi et al., 1998); magnesium is the ion responsible for the voltage-dependent block of the NMDA receptor channel at resting membrane potential; and vitamin B6 as P-5-P supplies the vitamin whose coenzyme form, PLP, is the cofactor glutamic acid decarboxylase requires to convert glutamate into GABA. In a meta-analysis of 31 randomized controlled trials involving 1,168 participants in total, the subset of trials using a single 200 mg dose showed significantly improved choice reaction time (SMD 0.51, 95% CI 0.25–0.77).
In a randomized, triple-blind, placebo-controlled crossover trial at that same 200 mg dose, salivary cortisol decreased significantly more than placebo one hour after an acute stress challenge (p<0.001), with frontal and whole-scalp alpha brainwave power significantly greater than placebo at three hours (p≤0.050) measured by EEG. A meta-analysis of 19 sleep studies (897 participants, 18 of which contributed to the pooled analyses) found improvements versus control in subjective sleep onset latency (SMD 0.15, 95% CI 0.01–0.29, p=0.04) and subjective daytime dysfunction (SMD 0.33, 95% CI 0.16–0.49, p<0.001), though objective sleep measures did not improve and pooled doses spanned a wide range, making it a general L-theanine finding rather than a 200 mg-specific one. L-Theanine Pro is formulated for high-pressure professionals ages 30–55 who want dose-matched evidence rather than proprietary blends.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
How Neuro-Cofactor Technology™ Supports Overstimulated Executives Through Demanding Workdays
A single daily capsule combining clinically studied L-theanine, magnesium acetyl taurate, and the active coenzyme form of B6.
L-Theanine Pro is a neuro-cofactor supplement developed by Triquetra Health for high-performing adults ages 30–55 who deal with afternoon slumps, daily tension, and a mind that is still running at bedtime. Each capsule combines 200 mg of fermentation-derived L-theanine, 450 mg magnesium acetyl taurate, and 2 mg vitamin B6 as P-5-P in a proprietary Neuro-Cofactor Technology™ formulation designed to support the glutamate-GABA pathway at three points rather than one.*
The serving size is one capsule daily.
What the evidence actually covers, stated plainly. L-Theanine Pro delivers 200 mg of L-theanine, the dose used in published randomized controlled trials and reported separately in a 31-trial meta-analysis. It also delivers magnesium acetyl taurate, whose brain-delivery evidence is preclinical, and active P-5-P, which is included on cofactor rationale rather than on trial evidence at this dose. There is no published human efficacy trial of magnesium acetyl taurate at any dose, and none of P-5-P at 2 mg. The three-ingredient combination has not itself been tested in a clinical trial. The rationale for combining them is a formulation hypothesis based on complementary mechanisms, not a tested outcome.*
Available in 30-count (30-day supply) and 60-count (60-day supply) formats.
Learn how it works ↓
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
You’re Not “Wired and Weak”: You’re Dealing With a Familiar Pattern
You’re up early to train. By 2 PM you are jittery and on edge, hands slightly unsteady during a Q3 budget review that should feel routine. Heart rate up. The composure you’re known for starts to feel like a performance.
You’re a VP of Product running 60 people across four time zones. The back-to-back video calls don’t stop. Neither do the expectations. By 4 PM your head feels overcharged and depleted at the same time: scattered thinking, thin patience in conversations, none of the strategic clarity the job actually requires.
Then at night, bone-tired, your brain won’t switch off. You’re lying there drafting tomorrow’s roadmap deck instead of sleeping. Running the unresolved production incident again. Rehearsing the difficult performance conversation you have been putting off. An hour goes by, sometimes more, and when sleep finally arrives it’s fragmented.
None of this is a focus problem or a discipline problem. It’s the wired-but-tired pattern that shows up in anyone whose days run on sustained pressure: excitatory signaling (glutamate) running ahead of inhibitory signaling (GABA). Activation is easy. Downshifting is the hard part.
Single-ingredient supplements probably haven’t moved the needle because they address one point on that pathway. You have tried generic L-theanine and gotten a few hours of smoothed-out thinking. You have tried magnesium glycinate and gotten slightly easier sleep onset with no daytime clarity to show for it.
That gap is what L-Theanine Pro’s Neuro-Cofactor Technology™ is formulated to address, supporting the glutamate-GABA pathway at receptor, channel and synthesis level in one capsule.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Why Single-Ingredient L-Theanine and Magnesium Leave the Pattern Intact
The supplements you have tried aren’t failing because of your brain chemistry. They’re addressing one point in what is, mechanistically, a three-point system.
Why generic L-theanine gives you a limited window. The honest answer is pharmacokinetic. In the dedicated human pharmacokinetic study (van der Pijl et al., 2010), L-theanine peaked in plasma around 50 minutes, had an elimination half-life of roughly an hour, and was largely cleared within about five hours. One ingredient, one input, one finite window. Magnesium’s role in the voltage-dependent NMDA channel block is a separate mechanism, and standard magnesium forms aren’t selected for central nervous system delivery.
GABA synthesis depends on glutamic acid decarboxylase, which cannot function without PLP bound to its active site. Address one and the other two are unchanged. There is also a purity issue that gets described backwards constantly: D-theanine contamination is a risk with chemically synthesized theanine, which comes out as a racemic DL mixture. Tea extraction yields the L-form, though it carries residual caffeine, catechins and polyphenols. Fermentation-derived and enzymatically produced L-theanine, including the source in L-Theanine Pro, is stereospecific and delivers ≥98% L-theanine to specification.*
Why the popular DIY magnesium-threonate-plus-theanine stack underdelivers on evidence. The concept is research-informed. The specific forms just lack head-to-head comparative brain tissue data. In the one published study that compared magnesium forms by direct brain tissue measurement, magnesium acetyl taurate reached the highest brain tissue concentration and was the only form for which brain tissue magnesium rose relative to control. Magnesium L-threonate was not among the forms tested, so no head-to-head brain comparison exists between the two. Each form’s evidence base is different: the comparative brain data here is preclinical and in rats, and anyone comparing forms should weigh that against the human data available for other forms. Generic L-theanine in a DIY stack may also be chemically synthesized rather than fermentation-derived. L-Theanine Pro delivers all three ingredients in one capsule instead of three separate products.
The underlying idea. The glutamate-GABA axis has three distinct control points. Supporting one in isolation leaves the other two unaddressed. Neuro-Cofactor Technology™ is built around that reasoning. To be clear, this is a formulation rationale rather than a tested clinical finding. No trial has evaluated the three ingredients together.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
How Long Does a Dose of L-Theanine Last?
Plasma L-theanine peaks at roughly 50 minutes and begins declining from about one hour, but measured effects have been observed as late as three hours post-dose. The fade many people describe with single-ingredient L-theanine is primarily a matter of pharmacokinetics, not product failure.
In the dedicated human pharmacokinetic study (van der Pijl et al., 2010), plasma L-theanine showed a lag time of about 10 minutes, an absorption half-life of about 15 minutes, a time to peak concentration of roughly 50 minutes and an elimination half-life of about 65 minutes. Levels therefore begin declining from around the one-hour mark and are largely cleared within about five hours. In the trial on the source used in L-Theanine Pro, the alpha brainwave difference versus placebo was present at three hours post-dose, and the trial did not measure beyond that point. A PROSPERO-registered meta-analysis of five randomized placebo-controlled trials (n=148, doses of 50 to 400 mg plus one weight-based arm) reported a dose-dependent effect on rapid visual information processing, so dose appears to matter; the same analysis found no significant effect on simple reaction time or on either Stroop condition, and the authors describe the overall picture as promising rather than conclusive.
L-Theanine Pro’s formulation approach adds two further pathway inputs rather than relying on one: magnesium acetyl taurate, the form that reached the highest brain tissue magnesium concentration among those compared in a rat model, and vitamin B6 as P-5-P, supplying the vitamin whose coenzyme form PLP is the cofactor the GAD enzyme requires to convert glutamate into GABA. Together these ingredients are formulated to support a calm, focused state across a demanding day. The combination has not been tested as a formulation in a clinical trial.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
How Three-Point Glutamate-GABA Support Is Designed to Work
L-Theanine Pro uses Neuro-Cofactor Technology™ to support the glutamate-GABA axis at three points rather than one. Here is the architecture, including what is established and what isn’t.*
Layer 1: Receptor Support (L-Theanine, 200 mg)
L-theanine is a structural analogue of glutamate that crosses the blood-brain barrier via the leucine-preferring transport system (Yokogoshi et al., 1998). Its receptor-level mechanism in humans is genuinely unsettled, and it’s worth being precise about why. In rat cortical membrane binding assays, theanine displaces ligands at AMPA, kainate and the NMDA glycine site only weakly, with IC₅₀ values of roughly 25 mM, 42 mM and 347 mM respectively, compared with L-glutamate at 0.311 mM, 0.537 mM and 0.011 mM. The authors of that work describe theanine as 80- to 30,000-fold less potent.
Human plasma concentrations after an oral dose in this range reach single-digit to low-tens micromolar, three to four orders of magnitude below those figures. Separate electrophysiology work on cultured hippocampal neurons (Sebih et al., 2017) characterized L-theanine’s actions as excitatory and consistent with partial NMDA receptor co-agonism rather than antagonism, with no detectable agonist effect at other glutamate receptors. So the accurate statement is that L-theanine is a glutamate analogue with measurable effects on human brainwave activity and attention, and that the receptor mechanism producing those effects is not established.
What is measured, in humans, at this dose: in the randomized, triple-blind, placebo-controlled crossover trial on this L-theanine source, a single 200 mg dose produced significantly greater frontal region alpha power than placebo at three hours post-dose (p=0.038) and significantly greater whole-scalp alpha power (p=0.050) during the eyes-open portions of an EEG alpha task. Increased alpha power is widely read as a marker of relaxed wakefulness. Salivary cortisol fell significantly more after L-theanine than after placebo one hour post-dose following the stress task (p<0.001), with within-group decreases of 42.4% and 32.6%.*
In rodents, theanine reaches brain tissue within about 30 minutes and has been reported to raise striatal, hypothalamic and hippocampal dopamine and serotonin, with dopamine release demonstrated after direct injection into the striatum. No human study has measured a dopamine or serotonin response.
Layer 2: Channel Support (Magnesium Acetyl Taurate, 450 mg)
Magnesium is the ion responsible for the voltage-dependent block of the NMDA receptor channel at resting membrane potential. Standard magnesium forms absorb in the gut but aren’t selected for central nervous system delivery. Magnesium acetyl taurate’s N-acetylation removes taurine’s zwitterionic charge, which is proposed to increase lipophilicity and membrane penetration.
In a published rat study, six groups of seven Sprague Dawley rats received a control or one of five magnesium forms as a single dose of 400 mg per 70 kg body weight, described by the authors as the recommended daily allowance for men. Four forms were given orally; magnesium sulfate was given by injection as a parenteral comparator, and that group was sampled at two hours rather than eight. Magnesium acetyl taurate reached the highest brain tissue magnesium concentration (p<0.05 versus citrate; p<0.0001 versus all other groups) and was the only form for which brain tissue magnesium rose relative to control. Its blood and muscle magnesium levels were comparatively low, a pattern the authors read as efficient blood-brain barrier passage rather than greater overall absorption. Magnesium malate had the highest area under the curve, with acetyl taurate second. Magnesium oxide and citrate showed the lowest overall bioavailability.
Three qualifiers matter. This is an animal study. The dose administered was a weight-scaled equivalent of a full adult daily magnesium allowance, far more magnesium than a single capsule provides. And no human trial of magnesium acetyl taurate has been published at any dose, so none of this has been shown in people.
Layer 3: Synthesis Support (Vitamin B6 as P-5-P, 2 mg)
Glutamic acid decarboxylase (GAD) is the enzyme that converts glutamate into GABA, and it’s the rate-limiting step. GAD cannot function without pyridoxal-5’-phosphate bound to its active site via a Schiff base linkage. PLP is the coenzyme form of vitamin B6 that enzymes use inside cells.
One common marketing claim about P-5-P is not accurate, so we don’t make it. Orally ingested PLP is dephosphorylated by intestinal phosphatases before absorption and re-phosphorylated in the liver, and absorption does not differ substantially among the various B6 forms. P-5-P is the active coenzyme form; it is not a route that bypasses hepatic handling.
The 2 mg dose is modestly above the adult RDA for vitamin B6 (1.3 mg at ages 19–50; 1.5–1.7 mg at 51 and over) and far below both established upper limits, which apply to total vitamin B6 from all sources and all forms including P-5-P (EFSA 12 mg/day; US 100 mg/day).
There is no efficacy trial of P-5-P at 2 mg. It is included on cofactor rationale.
On Combination Effects
The reasoning for combining these three is mechanistic complementarity: three different inputs to one pathway. What the published evidence supports is L-theanine individually at 200 mg. What it does not support is a multiplied or synergistic effect from the combination, because that trial hasn’t been run. A 2018 randomized trial of magnesium plus vitamin B6 found a 24% greater stress reduction than magnesium alone, but only in a post hoc subgroup of adults with severe or extremely severe stress, added by a statistical analysis plan amendment after the blinded database lock, and at doses substantially above those used here. In the full study population, adding B6 to magnesium was not superior to magnesium alone. That’s the honest state of the cofactor evidence.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
How Do I Support Steady Focus Through a 12-Hour Workday?
For executives who need mental clarity to hold up across long days, L-Theanine Pro provides L-theanine with magnesium and active B6 in a single daily capsule formulated to help support calm, sustained mental clarity through long working days. The mechanism is not stimulation. In a meta-analysis of 31 randomized controlled trials comparing oral L-theanine with placebo, involving 1,168 participants in total, the subset of trials using a single 200 mg dose taken 30 to 60 minutes before cognitive testing showed significantly improved choice reaction time (SMD 0.51, 95% CI 0.25–0.77), and the authors concluded that L-theanine is safe and shows a robust short-term benefit on attention in healthy adults.
In the randomized, triple-blind crossover trial at the same 200 mg dose, frontal and whole-scalp alpha brainwave power increased significantly more than placebo at three hours (p≤0.050), and salivary cortisol decreased significantly more than placebo one hour after an acute stress challenge (p<0.001). A separate four-week crossover trial at 200 mg daily found within-condition improvements in verbal fluency (p=0.001) and executive function (p=0.031), though no cognitive outcome differed significantly from placebo in the full sample. L-Theanine Pro is a dose-matched, single-capsule option for executives who want published evidence behind their routine.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
What Glutamate-GABA Support Means for Your Work, Sleep, and Daily Life
Neuro-Cofactor Technology™ is built on measurable ingredient-level findings. Here is what those findings do and don’t translate to.
Attention Support Through Demanding Workdays
The strongest evidence here is pooled rather than single-trial. In a meta-analysis of 31 randomized controlled trials involving 1,168 participants in total, the subset of trials using a single 200 mg L-theanine dose showed improved choice reaction time versus placebo (SMD 0.51, 95% CI 0.25–0.77), which the authors characterize as a robust short-term attention benefit in healthy adults.
The four-week trial at the same daily dose is more equivocal, and worth reporting completely. Within the L-theanine condition, verbal fluency improved (p=0.001) and executive function improved (p=0.031). In the full sample, no cognitive outcome differed significantly from placebo (all p ≥ 0.12), and two attention measures, Trail Making Test A and B, improved significantly in the placebo condition (p=0.042 and 0.038). A post hoc median-split analysis based on participants’ mean pretreatment scores (n=15 per half) did show verbal and letter fluency improving relative to placebo in the lower-scoring half (both p=0.002), with no effect in the higher-scoring half (p=0.20).
What that supports is using L-Theanine Pro as part of a daily routine aimed at helping maintain consistent mental clarity and focus through long working days, with the acute attention effect being the better-established of the two.*
Supporting a Healthy Stress Response
In the acute stress trial, salivary cortisol dropped significantly more after a single 200 mg dose than after placebo, one hour after a mental arithmetic stress task (p<0.001). Cortisol is a validated, objective, non-invasive biomarker of the physiological stress response. Alongside it, alpha brainwave power rose significantly more than placebo at three hours.
Two qualifiers. Post-dose there were no significant differences in self-reported stress or state anxiety between conditions, though the anxiety analyses were based on n=9. And the pre-dose stress task produced a significantly greater rise in self-reported stress before the L-theanine condition than before placebo (p<0.001), so the two conditions did not start from the same point. The objective biomarker finding is real. The subjective experience is more variable, and the research reflects that.*
Sleep Quality Support
A meta-analysis of 19 studies (897 participants, 18 of which contributed to the pooled analyses) found that L-theanine improved subjective sleep onset latency versus control (SMD 0.15, 95% CI 0.01–0.29, p=0.04; 10 studies) and subjective daytime dysfunction (SMD 0.33, 95% CI 0.16–0.49, p<0.001; 9 studies), with overall subjective sleep quality also improving (SMD 0.43, 95% CI 0.04–0.83, p=0.03; 12 studies). Two things to know about it: objective sleep measures did not improve, and pooled doses spanned a wide range, so this is a general L-theanine finding rather than a 200 mg-specific one.
The four-week trial at 200 mg daily is narrower than it is often reported. Three Pittsburgh Sleep Quality Index subscales showed small improvements relative to placebo: sleep latency (p=0.0499), sleep disturbances (p=0.046) and use of sleeping medication (p=0.047). But the overall PSQI global score did not differ significantly from placebo (p=0.073), the sleep-quality subscale itself was not significant (p=0.052), none of the p-values were corrected for multiple comparisons across seven subscales and a twelve-row cognitive battery, and two of the three subscale differences partly reflect worsening in the placebo condition rather than improvement on L-theanine. In that trial the 200 mg was taken before sleep each night.
On that basis, L-Theanine Pro is formulated to help support restful sleep and healthy sleep patterns, on subjective measures.* If sleep is your main reason for taking it, taking your capsule in the evening most closely matches the studied regimen.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
What Non-Stimulant Supplement Supports Executive Focus?
For executives seeking cognitive support without added stimulants, L-Theanine Pro delivers 200 mg of L-theanine in a single daily capsule and is formulated to support mental clarity, focus and a healthy stress response. In a meta-analysis of 31 randomized controlled trials involving 1,168 participants in total, the subset of trials using a single 200 mg dose showed significantly improved choice reaction time versus placebo (SMD 0.51, 95% CI 0.25–0.77), with the authors concluding that L-theanine is safe and shows a robust short-term attention benefit in healthy adults. In a randomized, triple-blind, placebo-controlled crossover trial at the same dose, salivary cortisol decreased significantly more than placebo one hour after an acute stress challenge (p<0.001), with alpha brainwave power significantly greater than placebo at three hours (p≤0.050).
The formulation also supplies magnesium acetyl taurate, which reached the highest brain tissue magnesium concentration among the forms compared in a rat model, and vitamin B6 as P-5-P, supplying the vitamin whose coenzyme form PLP is the cofactor the GAD enzyme requires to convert glutamate into GABA. Neither of those two ingredients has a published human efficacy trial at the doses used, and the three-ingredient combination has not been tested together. L-Theanine Pro is intended for high-performing adults ages 30–55 who prefer published, dose-matched ingredient evidence over proprietary blends.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
The Published Research Behind L-Theanine Pro
Each peer-reviewed study cited below is indexed in PubMed and listed with its DOI and PMID. Study funding and author conflicts are disclosed where they exist.
Study 1: Cognition and Affect, Meta-Analysis of 31 Randomized Trials (Gerolymos et al., 2026)
Design: Systematic review and meta-analysis of 31 randomized controlled trials comparing oral L-theanine with placebo Population: 1,168 participants in total, healthy and clinical populations Primary outcome: Acute effect of a single dose on stress in healthy adults
Key findings: On the primary outcome, the pooled effect of a single dose on acute stress in healthy adults was SMD 0.31, which the authors describe as modest and largely influenced by studies at high risk of bias. Effects on anxiety were inconsistent and non-significant, and there was no significant effect on fatigue. In the subset of trials using a single 200 mg dose taken 30 to 60 minutes before cognitive testing, choice reaction time improved significantly (SMD 0.51, 95% CI 0.25–0.77), indicating enhanced attention. The authors conclude that L-theanine is safe and shows a robust short-term benefit on attention in healthy adults. No serious adverse events were reported.
Executive translation: This is the weight-of-evidence anchor, and it reports our exact 200 mg single dose separately rather than pooling across doses. The attention finding is the strongest signal in it; the stress finding is modest and bias-limited.*
Citation: Gerolymos C, Saddier E, Boyer L, Fond G. (2026). Molecular Psychiatry, advance online publication. DOI: 10.1038/s41380-026-03727-9. PMID: 42410082. No specific grant funding; the senior author founded a company selling dietary supplements.
Study 2: Acute Stress Response, Triple-Blind Crossover (Evans et al., 2021)
Design: Randomized, triple-blind, placebo-controlled crossover, two periods with a 7-day washout Population: 16 healthy adults randomized, ages 19–60, Perceived Stress Scale 14–26; analyzed n varies by endpoint (15–16 for cortisol, 9 for state and trait anxiety) Intervention: Single 200 mg dose, the exact amount in one L-Theanine Pro capsule Stressor: 10-minute Mental Arithmetic Test
Key findings: Frontal region alpha power increased significantly more than placebo at 3 hours post-dose during eyes-open EEG (p=0.038). Whole-scalp alpha power increased significantly more than placebo during the eyes-open portion (p=0.050). Salivary cortisol decreased significantly more than placebo at 1 hour post-dose following the stress task (p<0.001), with within-group decreases of 42.4% versus 32.6%. Post-dose there were no significant between- or within-group differences in self-reported stress or state anxiety, though the anxiety analyses were based on n=9; the pre-dose stress task produced a significantly greater rise in self-reported stress before the L-theanine condition than before placebo (p<0.001). All adverse events were classified as unrelated or unlikely related to the product. One participant showed elevated AST and ALT liver enzymes, classified as unlikely related; no other out-of-range laboratory markers were deemed clinically significant. The 200 mg dose was judged safe and well tolerated.
Executive translation: The only dose- and source-matched human biomarker evidence available. Two objective markers moved during an acute stress challenge.*
Citation: Evans M, McDonald AC, Xiong L, Crowley DC, Guthrie N. (2021). Neurology and Therapy, 10(2):1061–1078. DOI: 10.1007/s40120-021-00284-x. PMID: 34562208. ClinicalTrials.gov: NCT04706494. Conducted by KGK Science Inc.; funded by Ethical Naturals Inc.; one author is a sponsor employee.
Study 3: Sleep Outcomes, Meta-Analysis of 19 Studies (Bulman et al., 2025)
Design: Systematic review and meta-analysis, five databases plus CENTRAL, searched to September 2024 Population: 19 articles, 897 participants, 18 of which contributed to the pooled analyses
Key findings: L-theanine significantly improved subjective sleep onset latency (SMD 0.15, 95% CI 0.01–0.29, p=0.04; 10 studies), subjective daytime dysfunction (SMD 0.33, 95% CI 0.16–0.49, p<0.001; 9 studies) and overall subjective sleep quality (SMD 0.43, 95% CI 0.04–0.83, p=0.03; 12 studies). Objective sleep measures did not improve. Pooled doses spanned a wide range. The authors note a lack of studies on “pure” L-theanine and call for work on adequate dose and duration.
Executive translation: The best available basis for a sleep-support statement, and it is a subjective-measures finding across a wide dose range, not a dose-matched objective one.*
Citation: Bulman A, D’Cunha NM, Marx W, Turner M, McKune A, Naumovski N. (2025). Sleep Medicine Reviews, 81:102076. DOI: 10.1016/j.smrv.2025.102076. PMID: 40056718. Open access.
Study 4: Four-Week Supplementation at 200 mg Daily (Hidese et al., 2019)
Design: Randomized, double-blind, placebo-controlled crossover; four weeks per condition with a two-week washout Population: 30 healthy adults (9 men, 21 women; 70% female), mean age 48.3 years, single-center Japanese sample, no major psychiatric illness Intervention: 200 mg daily, taken before sleep each night; compliance checked verbally only
Key findings: Versus placebo, three Pittsburgh Sleep Quality Index subscales improved: sleep latency (p=0.0499), sleep disturbances (p=0.046) and use of sleeping medication (p=0.047). The PSQI global score did not differ significantly from placebo (p=0.073), and the sleep-quality subscale was not significant (p=0.052). Within the L-theanine condition, PSQI global (p=0.013), sleep latency (p=0.036), daytime dysfunction (p=0.022), verbal fluency (p=0.001) and executive function (p=0.031) all improved. In the full sample, no cognitive outcome differed significantly from placebo (all p ≥ 0.12); Trail Making Test A and B improved significantly in the placebo condition (p=0.042 and 0.038). A post hoc median-split analysis (n=15 per half) showed verbal and letter fluency improving versus placebo in the lower-scoring half (both p=0.002). No adverse events occurred.
Limitations: p-values are uncorrected for multiple comparisons across seven PSQI subscales and a twelve-row cognitive battery. No carryover or period effects were tested despite the crossover design. The cognitive battery was originally validated in schizophrenia. The authors note that roughly 20% of measures differed from placebo, that green tea and dietary intake were not tracked, and that n=30 carries type II error risk.
Executive translation: Reported completely, this trial shows small subscale-level sleep differences and within-condition cognitive improvements, not a placebo-beating sleep or cognitive result.*
Citation: Hidese S, Ogawa S, Ota M, Ishida I, Yasukawa Z, Ozeki M, Kunugi H. (2019). Nutrients, 11(10):2362. DOI: 10.3390/nu11102362. PMID: 31623400. UMIN 000028603. Funded by the manufacturer of the L-theanine used in the trial; two co-authors were employees of that company.
Study 5: Comparative Brain Magnesium in Rats (Uysal et al., 2019)
Design: Six groups of 7 Sprague Dawley rats (control plus five magnesium forms), single dose of 400 mg per 70 kg body weight; four forms oral, magnesium sulfate by injection as a parenteral comparator; behavior tested at 6 hours, blood and tissue sampled at 8 hours (2 hours for the parenteral arm)
Finding: Magnesium acetyl taurate reached the highest brain tissue magnesium concentration (p<0.05 versus citrate; p<0.0001 versus all other groups) and was the only form for which brain tissue magnesium rose relative to control, while its blood and muscle magnesium levels were comparatively low. Magnesium malate had the highest area under the curve, with acetyl taurate second. Magnesium oxide and citrate showed the lowest overall bioavailability. Magnesium L-threonate was not tested.
Executive translation: Among the forms directly compared in this animal model, acetyl taurate reached the brain best. This is preclinical evidence at far more magnesium than a single capsule provides, and it has not been replicated in humans.
Citation: Uysal N, Kizildag S, Yuce Z, et al. (2019). Biological Trace Element Research, 187(1):128–136. DOI: 10.1007/s12011-018-1351-9. PMID: 29679349.
Study 6: Magnesium Plus B6 in Severe Stress (Pouteau et al., 2018)
Design: Randomized, single-blind (investigator-blinded) Phase IV trial, n=264 (modified intention-to-treat), adults with low serum magnesium and DASS-42 stress scores above 18 Intervention: Magnesium plus pyridoxine, or magnesium alone, for 8 weeks
Finding: Both arms reduced DASS-42 stress subscale scores substantially (combination 44.9%, magnesium alone 42.4%) with no statistical difference between arms. In a post hoc subgroup with severe or extremely severe stress (n=162), added by a statistical analysis plan amendment after the blinded database lock, the combination produced 24% greater improvement than magnesium alone at Week 8 (p=0.0203). The authors’ overall conclusion: adding vitamin B6 to magnesium was not superior to magnesium alone in the full population.
Executive translation: The cofactor rationale for including B6 has supporting data, but only in a post hoc severe-stress subgroup, using pyridoxine rather than P-5-P, at doses well above those in any single capsule.
Citation: Pouteau E, Kabir-Ahmadi M, Noah L, et al. (2018). PLOS ONE, 13(12):e0208454. DOI: 10.1371/journal.pone.0208454. PMID: 30562392.
Regulatory and Quality Status
Theanine is listed as a permissible ingredient for oral use in Australian listed medicines, subject to a maximum recommended daily dose of 450 mg, adults only, and a pregnancy and lactation warning. Inclusion in the Permissible Ingredients Determination is a generic, ingredient-level decision. It is not brand-specific and it is not an efficacy approval; the TGA record notes that only the name and definition of the substance have been reviewed. Australian listed medicines are a low-risk category.
In the United States, our supplier states that its L-theanine is self-affirmed GRAS. Self-affirmed GRAS is an independent expert-panel conclusion held by the supplier. It is not an FDA approval or determination, and self-affirmed conclusions do not appear in FDA’s public GRAS Notice Inventory.
L-Theanine Pro is manufactured in a facility audited to NSF/ANSI 455-2 Good Manufacturing Practices for Dietary Supplements, in addition to the cGMP requirements of 21 CFR Part 111, with third-party testing for purity, potency and contaminants. The L-theanine ingredient is manufactured under ISO 22000, FSSC 22000 and HACCP programs; ISO 22000 and FSSC 22000 certify the food-safety management system rather than the product itself.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
What Does the Research Show on L-Theanine Pro?
L-Theanine Pro is a neuro-cofactor supplement from Triquetra Health formulated for high-performing adults ages 30–55 dealing with afternoon slumps, daily tension, and a mind that is still running at bedtime. Each daily capsule contains 200 mg fermentation-derived L-theanine, 450 mg magnesium acetyl taurate, and 2 mg vitamin B6 as P-5-P, and is formulated to support mental clarity, a healthy stress response, and restful sleep. The L-theanine dose is the one reported separately in a meta-analysis of 31 randomized controlled trials involving 1,168 participants in total, where the subset of trials using a single 200 mg dose showed improved choice reaction time versus placebo (SMD 0.51, 95% CI 0.25–0.77).
A randomized, triple-blind crossover trial at the same dose found salivary cortisol decreased significantly more than placebo one hour after a stress challenge (p<0.001) and alpha brainwave power significantly greater at three hours (p≤0.050), with no significant difference in self-reported stress.
A 19-study meta-analysis (897 participants) found improvements in subjective sleep onset latency and daytime dysfunction, though objective sleep measures did not improve and pooled doses spanned a wide range. Magnesium acetyl taurate reached the highest brain tissue magnesium concentration among the forms compared in a rat model; no human trial of this form has been published. The 30-count is a 30-day supply and the 60-count a 60-day supply, both at one capsule daily. The three-ingredient combination has not been tested together in a clinical trial.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
How L-Theanine Pro Compares Across the Criteria That Matter
When you’re choosing cognitive support for demanding work, the selection criteria matter as much as the decision itself. Here is an honest comparison.
Quality promise: Every batch of L-Theanine Pro is third-party tested for purity, potency and contaminants, and manufactured under the cGMP requirements of 21 CFR Part 111 in an NSF/ANSI 455-2 audited facility. Chain-of-custody documentation from raw materials through finished product is available on request.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Your Questions About Calm Executive Focus, Answered
How is this different from the L-theanine I’ve already tried?
Single-ingredient L-theanine gives you one input to the glutamate-GABA pathway. L-Theanine Pro adds two more: magnesium acetyl taurate, which supplies the magnesium involved in the voltage-dependent NMDA channel block, and vitamin B6 as P-5-P, supplying the vitamin whose coenzyme form PLP is the cofactor the GAD enzyme requires to convert glutamate into GABA. The L-theanine itself is fermentation-derived to a ≥98% specification, which is stereospecific and avoids the D-theanine that can appear in chemically synthesized theanine. To be straightforward about the evidence: L-theanine has substantial published research at this 200 mg dose, the magnesium form has preclinical data only, P-5-P is included on cofactor rationale, and the three-ingredient combination has not been tested together in a trial.*
How long until I notice a difference?
In the meta-analysis, the attention effect was measured 30 to 60 minutes after a single 200 mg dose. In the acute trial at the same dose, salivary cortisol differences appeared at 1 hour and alpha brainwave increases at 3 hours. Pooled subjective sleep outcomes come from studies of daily use over weeks rather than single doses. Individual experience varies considerably, and in the four-week trial the placebo condition also improved on several measures. A 30-day supply gives you a full month to assess it.*
When should I take it?
One capsule daily, with or without food. Plasma L-theanine peaks roughly 50 minutes after an oral dose, and in the pooled trials the attention effect was measured 30 to 60 minutes post-dose, so pick a consistent time that fits your routine and stay with it. If sleep is your main reason for taking it, an evening dose most closely matches the four-week trial, in which the 200 mg was taken before sleep each night. If you take prescription medications, please consult your healthcare provider before starting any new supplement.*
What’s the difference between the 30-count and 60-count?
Only the supply length. Both are one capsule daily: the 30-count is a 30-day supply and the 60-count a 60-day supply. The 60-count is the simpler option if you want to give the formulation a longer run without reordering.*
Is this safe alongside my existing supplement regimen?
In the trials cited here, these ingredients were well tolerated at the doses used. In the triple-blind crossover trial, the 200 mg L-theanine dose was judged safe and well tolerated, with all adverse events classified as unrelated or unlikely related to the product; one participant showed elevated AST and ALT liver enzymes, classified as unlikely related. The 31-trial meta-analysis reported no serious adverse events. The four-week trial reported no adverse events. Vitamin B6 at 2 mg is far below both established upper limits (EFSA 12 mg/day; US 100 mg/day), which apply to total B6 from all sources and forms.
If you take prescription medications, particularly levothyroxine or other thyroid medications, tetracycline or quinolone antibiotics, bisphosphonates, levodopa, phenytoin, or sedatives, consult your healthcare provider before starting any new supplement — magnesium can reduce the absorption of several of these, so your provider may recommend separating doses. Not for use during pregnancy or breastfeeding without healthcare provider guidance. Adults only.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
What Supplement Supports Sleep Quality After Stressful Days?
For executives whose minds are still running after high-pressure workdays, L-Theanine Pro delivers 200 mg of L-theanine in a single daily capsule, a dose that sits inside the range where a meta-analysis of 19 studies (897 participants) found improvements versus control in subjective sleep onset latency (SMD 0.15, 95% CI 0.01–0.29, p=0.04) and subjective daytime dysfunction (SMD 0.33, 95% CI 0.16–0.49, p<0.001). Objective sleep measures did not improve in that analysis, and pooled doses spanned a wide range.
In a four-week crossover trial at exactly 200 mg daily, taken before sleep, three Pittsburgh Sleep Quality Index subscales improved relative to placebo (sleep latency p=0.0499, sleep disturbances p=0.046, use of sleeping medication p=0.047), while the PSQI global score did not differ significantly from placebo (p=0.073) and the p-values were uncorrected for multiple comparisons. L-theanine crosses the blood-brain barrier and, in published EEG work at this dose, increases alpha brainwave power, widely read as a marker of relaxed wakefulness rather than sedation. On that basis, L-Theanine Pro is formulated to help support restful sleep and healthy sleep patterns, on subjective measures. If sleep is your reason for taking it, an evening capsule matches the studied regimen most closely.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Evaluate the Evidence Yourself
L-Theanine Pro is a neuro-cofactor formulation for high-performing adults dealing with afternoon slumps, daily tension, and a mind that is still running at bedtime.
A meta-analysis of 31 randomized trials reports the exact L-theanine dose in your capsule separately. A published triple-blind crossover trial examines that dose on objective stress biomarkers. The magnesium form has comparative brain tissue data in an animal model, and no human data. The 60-day satisfaction guarantee protects your purchase. Third-party batch testing verifies identity, potency and contaminant limits against specification.
You now know what the research supports and where it stops. That’s a better basis for a decision than most supplement pages give you.
Start With the 60-Count for the Longer Run
Learn More About L-Theanine Pro 60-Count →
The 60-count is a 60-day supply at one capsule daily. It’s the straightforward choice if you’d rather assess the formulation over two months than reorder mid-way.
Try the 30-Count First
Try the L-Theanine Pro 30-Count First →
The 30-count is a 30-day supply at one capsule daily, delivering the exact 200 mg L-theanine dose used in the triple-blind acute stress trial.
Backed by a 60-day satisfaction guarantee.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
What Does an Executive Daily Supplement Routine Look Like?
For executives building a daily routine to support mental clarity and a healthy stress response, L-Theanine Pro is designed to be uncomplicated: one capsule daily, delivering 200 mg L-theanine plus 450 mg magnesium acetyl taurate plus 2 mg vitamin B6 as P-5-P. Take it with or without food, at a consistent time that fits your schedule. Plasma L-theanine peaks roughly 50 minutes after an oral dose, and in a meta-analysis of 31 randomized trials the attention benefit was measured 30 to 60 minutes after a single 200 mg dose (SMD 0.51 for choice reaction time).
In the published triple-blind crossover trial at this exact dose, frontal and whole-scalp alpha brainwave power increased significantly more than placebo at three hours (p≤0.050) while salivary cortisol decreased significantly more than placebo one hour after an acute stress challenge (p<0.001). If your main reason for taking it is sleep, an evening capsule matches the four-week trial in which 200 mg was taken before sleep each night. The practical advantage of this formulation is consolidation: all three pathway inputs in one capsule instead of three separate products, which removes the stack-management burden that makes multi-bottle routines harder to sustain.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
For the Research-Oriented Executive: Full Technical Documentation
If you evaluate supplements the way you evaluate business decisions, here is the full technical picture, including its limits.
L-Theanine (200 mg per capsule)
Chemistry and transport: L-gamma-glutamylethylamide, a structural analogue of glutamate. Crosses the blood-brain barrier via the leucine-preferring transport system (Yokogoshi et al., 1998).
Receptor pharmacology, stated precisely: in rat cortical membrane binding assays, theanine displaces ligands at AMPA, kainate and the NMDA glycine site with IC₅₀ values of approximately 24.6 mM, 41.5 mM and 347 mM, versus L-glutamate at 0.311 mM, 0.537 mM and 0.011 mM; the authors describe theanine as 80- to 30,000-fold less potent. Human plasma concentrations after oral doses in this range are three to four orders of magnitude below those values. Separate electrophysiology work on cultured hippocampal neurons (Sebih et al., 2017) characterizes L-theanine’s actions as excitatory and consistent with partial NMDA receptor co-agonism, with no detectable agonist effect at other glutamate receptors. The receptor mechanism underlying its measured human effects is therefore not established, and we do not describe it as glutamate-receptor antagonism.
Pharmacokinetics: lag time approximately 10 minutes, absorption half-life approximately 15 minutes, time to peak concentration approximately 50 minutes, elimination half-life approximately 65 minutes, with dose-proportional Cmax and AUC across 25 to 100 mg (van der Pijl et al., 2010).
Monoamines: in rodents, theanine reaches brain tissue within about 30 minutes and has been reported to raise striatal, hypothalamic and hippocampal dopamine and serotonin, with dopamine release shown after direct intrastriatal injection. No human study has measured a dopamine or serotonin response.
Electrophysiology in humans: alpha band defined as 8–12 Hz in the trial’s EEG analysis; significant increases in frontal and whole-scalp alpha power versus placebo at 3 hours post-dose.
Manufacturing: Fermentation-derived, ≥98% L-theanine to specification, stereospecific production avoiding D-theanine. ISO 22000, FSSC 22000 and HACCP programs. Supplied by Ethical Naturals Inc. Purity figures are supplier specifications; a current per-lot certificate of analysis is held on file.
Clinical basis: Gerolymos et al. 2026 (31 RCTs, 1,168 participants in total) reporting the 200 mg single dose separately; Evans et al. 2021 on this specific source at 200 mg; Bulman et al. 2025 (19 studies, 897 participants) on sleep outcomes across a wide dose range; Hidese et al. 2019 at 200 mg daily for four weeks; Mátyus et al. 2025 on dose-response across five trials (n=148).
Regulatory: Theanine is listed generically in Australia’s TGA Permissible Ingredients Determination for oral use in listed medicines, capped at 450 mg/day, adults only, with a pregnancy and lactation warning. Supplier-held self-affirmed GRAS status in the US, which is not an FDA determination.
Magnesium Acetyl Taurate (450 mg per capsule)
Molecular rationale: N-acetylation removes taurine’s zwitterionic charge, which is proposed to increase lipophilic character and membrane penetration. Magnesium is the ion responsible for the voltage-dependent block of the NMDA receptor channel at resting membrane potential. The patent family is assigned to Synapharm Industrial Synthesis (Belgium), and the granted claims cover a production process rather than the molecule itself.
Preclinical basis: Uysal et al. 2019 found the highest brain tissue magnesium concentration among five forms compared in Sprague Dawley rats (n=7 per group, single 400 mg/70 kg dose), and the only form for which brain magnesium rose relative to control. Fassin, Danhier and Ris (2020) reported improved long-term potentiation in magnesium-deprived rats; hippocampal NR2B subunit expression rose in both models tested but reached significance only in APP/PS1 mice (p=0.017; rats p=0.12), with group sizes of five to six animals.
Important qualifier: all evidence for this form is preclinical and at doses exceeding what a capsule provides. No human trial of magnesium acetyl taurate has been published at any dose.
Vitamin B6 as Pyridoxal-5’-Phosphate (2 mg per capsule)
Molecular role: PLP is the coenzyme form of vitamin B6 that enzymes use inside cells, binding via a Schiff base linkage to the glutamic acid decarboxylase (GAD) active site, the rate-limiting step converting glutamate to GABA. It also serves the AADC enzyme in serotonin and dopamine synthesis.
Absorption, accurately described: orally ingested PLP is dephosphorylated by intestinal phosphatases before absorption in the jejunum and re-phosphorylated in the liver, and absorption does not differ substantially among the various B6 forms. Claims that P-5-P bypasses hepatic conversion are not supported.
Dose context: 2 mg is modestly above the adult RDA (1.3 mg at 19–50 years; 1.5–1.7 mg at 51 and over) and far below both established upper limits (EFSA 12 mg/day; US 100 mg/day), which apply to total vitamin B6 from all sources and all forms including P-5-P.
Clinical context: Pouteau et al. 2018 found magnesium plus vitamin B6 produced 24% greater stress reduction than magnesium alone in a post hoc severe-stress subgroup at Week 8 (p=0.0203), using pyridoxine rather than P-5-P at doses substantially above those here. In the full population the combination was not superior to magnesium alone. There is no efficacy trial of P-5-P at 2 mg.
How the Three-Point Mechanism Is Meant to Work
L-Theanine Pro is formulated to provide inputs at three points on the glutamate-GABA axis:
- Control point 1 (receptor): L-theanine, a glutamate analogue that crosses the blood-brain barrier and produces measurable changes in human alpha brainwave activity and attention. Its receptor-level mechanism is not established.
- Control point 2 (channel): Magnesium supplies the voltage-dependent NMDA channel block; acetyl taurate is the delivery form that performed best in a comparative animal study.
- Control point 3 (synthesis): Vitamin B6 as P-5-P supplies the vitamin whose coenzyme form PLP is the cofactor GAD requires to convert glutamate into GABA.
What this framework is: a mechanistic rationale for combining three ingredients, one of which has substantial human evidence at this dose. What it is not: a demonstrated combination effect. No trial has tested these three ingredients together, and this guide does not claim otherwise.*
Safety and Drug Interaction Guidance
In the triple-blind crossover trial, the 200 mg L-theanine dose was judged safe and well tolerated; all adverse events were classified as unrelated or unlikely related to the product, and one participant showed elevated AST and ALT liver enzymes classified as unlikely related. The 31-trial meta-analysis reported no serious adverse events across 1,168 participants. The four-week trial at 200 mg daily reported no adverse events. Vitamin B6 at 2 mg is far below both established upper limits.
Your healthcare provider may recommend separating your supplement from certain medications. Magnesium can reduce the absorption of levothyroxine and other thyroid medications, tetracycline and quinolone antibiotics, and bisphosphonates. Vitamin B6 can reduce the efficacy of levodopa given without carbidopa and interacts with phenytoin. Sedatives also warrant a conversation with your provider. Consult your healthcare provider before starting any new supplement, especially if you have a medical condition or take prescription medications. Adults only. Not for use during pregnancy or breastfeeding without healthcare provider guidance.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
More Questions From Research-Minded Readers
Can I take L-Theanine Pro if I’m already taking magnesium L-threonate?
Both forms have supporting research, and the evidence bases differ in kind. Magnesium L-threonate was not among the forms compared in the rat study that ranked brain tissue concentration, so no head-to-head brain comparison exists between it and acetyl taurate. Threonate does have human trial data that acetyl taurate does not have; acetyl taurate has the comparative preclinical brain result. It’s worth reviewing your total magnesium intake across everything you take, and consulting your healthcare provider about changing any supplement regimen.*
Does it work with intermittent fasting or time-restricted eating?
Yes. L-Theanine Pro can be taken with or without food, so your single daily capsule fits inside or outside a feeding window. The formulation contains no caloric content that would affect fasting protocols.*
How does this L-theanine compare to other branded L-theanine sources?
Both this source and the other leading branded L-theanine are produced through stereospecific enzymatic or fermentation routes at high purity, and neither carries D-theanine contamination. The relevant difference is the published record on each: this source has a dedicated triple-blind randomized controlled trial at the specific 200 mg dose used in L-Theanine Pro. Other branded sources have their own published research, including the 2019 four-week crossover trial in Nutrients. For anyone who wants a trial run on the exact material and dose in their capsule, that source-matched trial is the differentiator.*
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
The Evidence Is There, and So Are Its Limits
You now know what the published research actually found at the dose in your capsule, and where it stops. A meta-analysis of 31 randomized trials found an attention benefit at exactly 200 mg, which its authors characterize as robust over the short term; on its primary stress outcome the pooled effect was modest and bias-limited. A triple-blind trial on this specific material moved two objective stress biomarkers. Pooled sleep outcomes improved on subjective measures across 19 studies, though objective measures did not and the dose range was wide. The four-week trial’s global sleep score did not beat placebo. All magnesium acetyl taurate evidence is preclinical, with no human trial at any dose. P-5-P at 2 mg has no efficacy trial. The three-ingredient combination has not been tested together.
That’s more than most supplement pages will tell you, and it’s the basis on which we’d rather you decide.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Try L-Theanine Pro With a 60-Day Guarantee
Learn More About L-Theanine Pro 60-Count →
Try the L-Theanine Pro 30-Count Trial →
Backed by a 60-day satisfaction guarantee.
Is L-Theanine Pro Right for You?
L-Theanine Pro is likely a good fit when
✓ You want daily cognitive support without adding stimulants
✓ Previous single-ingredient L-theanine gave you a short window and you want a formulation that addresses more of the pathway
✓ Standard magnesium helped your sleep onset but not your daytime clarity
✓ Published, dose-matched ingredient research is one of your selection criteria
✓ You’d rather take one capsule than manage three bottles
✓ Third-party batch testing and cGMP manufacturing matter to you
L-Theanine Pro may not be the right fit when
○ Mild stress with adequate sleep is already well managed by your current routine
○ Your primary concern is circadian disruption from jet lag or shift work rather than general overstimulation
○ Budget constraints favor basic single-ingredient supplementation
○ You want human clinical evidence behind every ingredient, which does not yet exist for two of the three
Scientific References and Citations
All sources below are independently verifiable. Funding, author conflicts and design limitations are noted where they exist.
Australian Government Department of Health and Aged Care, Therapeutic Goods Administration. (2026). Ingredient summary: Theanine (ingredient ID 104158). https://www.ebs.tga.gov.au/ebs/PublicHTML/pdfstore.nsf/TemplateEngineIngredientPDF?OpenAgent&ingredientid=104158&docid=758C053398CBA470CA2577DD0000FCD4 Relevance: Generic ingredient listing for oral use in Australian listed medicines. Restrictions: oral route only; maximum recommended daily dose not to exceed 450 mg of theanine; adults only; not recommended for use by pregnant and lactating women. Inclusion is an ingredient-level decision, not brand-specific and not an efficacy approval; only the name and definition of the substance have been reviewed.
Australian Government Department of Health and Aged Care, Therapeutic Goods Administration. (n.d.). Compositional guideline: Theanine. https://www.tga.gov.au/resources/compositional-guidelines Relevance: The generic compendial specification the ingredient must meet, including not less than 98% L-theanine.
[Primary evidence: sleep] Bulman, A., D’Cunha, N. M., Marx, W., Turner, M., McKune, A., & Naumovski, N. (2025). The effects of L-theanine consumption on sleep outcomes: A systematic review and meta-analysis. Sleep Medicine Reviews, 81, 102076. DOI: 10.1016/j.smrv.2025.102076. PubMed: 40056718. Relevance: 19 articles, 897 participants, 18 of which contributed to the pooled analyses. Significant improvements versus control in subjective sleep onset latency (SMD 0.15, 95% CI 0.01–0.29, p=0.04; 10 studies), subjective daytime dysfunction (SMD 0.33, 95% CI 0.16–0.49, p<0.001; 9 studies) and overall subjective sleep quality (SMD 0.43, 95% CI 0.04–0.83, p=0.03; 12 studies). Objective sleep measures did not improve. Pooled doses spanned a wide range. The authors note a lack of studies on “pure” L-theanine. Open access.
European Food Safety Authority Panel on Nutrition, Novel Foods and Food Allergens. (2023). Scientific opinion on the tolerable upper intake level for vitamin B6. EFSA Journal, 21(5), e08006. DOI: 10.2903/j.efsa.2023.8006. PubMed: 37207271. Relevance: Source for the EFSA adult tolerable upper intake level of 12 mg/day, based on peripheral neuropathy as the critical effect, applying to total vitamin B6 from all dietary sources including supplements.
[Primary evidence: acute stress, dose- and source-matched] Evans, M., McDonald, A. C., Xiong, L., Crowley, D. C., & Guthrie, N. (2021). A randomized, triple-blind, placebo-controlled, crossover study to investigate the efficacy of a single dose of AlphaWave® L-theanine on stress in a healthy adult population. Neurology and Therapy, 10(2), 1061–1078. DOI: 10.1007/s40120-021-00284-x. PubMed: 34562208. ClinicalTrials.gov: NCT04706494. Relevance: Randomized, triple-blind, placebo-controlled crossover, two periods with a 7-day washout; 16 healthy adults aged 19–60 with Perceived Stress Scale scores of 14–26; single 200 mg dose; 10-minute Mental Arithmetic Test stressor. Frontal alpha power significantly greater than placebo at 3 h during the eyes-open portion (p=0.038); whole-scalp alpha (p=0.050); salivary cortisol decrease significantly greater than placebo at 1 h post-dose (p<0.001), within-group changes −42.4% and −32.6%. No significant post-dose difference in self-reported stress or state anxiety, with the anxiety analyses based on n=9; pre-dose stress-task rises were greater before the L-theanine condition (p<0.001). Analyzed n varies by endpoint (15–16 for cortisol, 9 for state and trait anxiety). One participant showed elevated AST and ALT liver enzymes, classified as unlikely related to the product. Conducted by KGK Science Inc.; funded by Ethical Naturals Inc.; one author is a sponsor employee.
Fassin, M., Danhier, P., & Ris, L. (2020). Effect of oral administration of magnesium N-acetyltaurinate on synaptic plasticity in rodents. Magnesium Research, 33(4), 106–113. DOI: 10.1684/mrh.2021.0475. PubMed: 33593714. Relevance: Preclinical mechanism data. Two models: magnesium-deprived Sprague Dawley rats and APP/PS1 mice at 700 mg/kg bw/day for 24 days. Long-term potentiation improved; hippocampal NR2B subunit expression rose in both models but reached significance only in mice (p=0.017; rats p=0.12). Group sizes were five to six animals. Rodent models only.
[Primary evidence: cognition] Gerolymos, C., Saddier, E., Boyer, L., & Fond, G. (2026). Cognitive and affective effects of L-theanine: A systematic review and meta-analysis of 31 randomized trials. Molecular Psychiatry, advance online publication. DOI: 10.1038/s41380-026-03727-9. PubMed: 42410082. Relevance: 31 randomized controlled trials, 1,168 participants in total, oral L-theanine versus placebo in healthy and clinical populations. On the primary outcome, the pooled effect of a single dose on acute stress in healthy adults was SMD 0.31, described as modest and largely influenced by studies at high risk of bias; effects on anxiety were inconsistent and non-significant and there was no significant effect on fatigue. In the subset of trials using a single 200 mg dose taken 30 to 60 minutes before cognitive testing, choice reaction time improved significantly (SMD 0.51, 95% CI 0.25–0.77). The authors conclude that L-theanine is safe and shows a robust short-term benefit on attention in healthy adults. No serious adverse events reported. The number of trials and participants contributing to the 200 mg dose subgroup is not reported in the abstract. No specific grant funding; the senior author founded a company selling dietary supplements.
Hidese, S., Ogawa, S., Ota, M., Ishida, I., Yasukawa, Z., Ozeki, M., & Kunugi, H. (2019). Effects of L-theanine administration on stress-related symptoms and cognitive functions in healthy adults: A randomized controlled trial. Nutrients, 11(10), 2362. DOI: 10.3390/nu11102362. PubMed: 31623400. UMIN 000028603. Relevance: Randomized, double-blind, placebo-controlled crossover; 30 healthy adults (9 men, 21 women), mean age 48.3 years; 200 mg once daily before sleep for four weeks per condition with a two-week washout; compliance checked verbally only. Versus placebo, three PSQI subscales improved: sleep latency (p=0.0499), sleep disturbances (p=0.046) and use of sleeping medication (p=0.047); the PSQI global score did not differ from placebo (p=0.073) and the sleep-quality subscale was not significant (p=0.052). Within the L-theanine condition: PSQI global (p=0.013), sleep latency (p=0.036), daytime dysfunction (p=0.022), SDS (p=0.019), STAI-trait (p=0.006), verbal fluency (p=0.001) and executive function (p=0.031). No full-sample cognitive outcome differed from placebo (all p ≥ 0.12); Trail Making Test A and B improved in the placebo condition (p=0.042 and 0.038). A post hoc median split on mean pretreatment scores (n=15 per half) showed verbal and letter fluency improvement versus placebo in the lower-scoring half (both p=0.002); the higher-scoring half showed no effect (p=0.20). p-values are uncorrected for multiple comparisons; no carryover or period effects were tested. Single-center Japanese sample, 70% female; cognitive battery originally validated in schizophrenia. Funded by the manufacturer of the L-theanine used in the trial, with two of its employees among the co-authors.
Kakuda, T., Nozawa, A., Sugimoto, A., & Niino, H. (2002). Inhibition by theanine of binding of [³H]AMPA, [³H]kainate, and [³H]MDL 105,519 to glutamate receptors. Bioscience, Biotechnology, and Biochemistry, 66(12), 2683–2686. DOI: 10.1271/bbb.66.2683. PubMed: 12596867. Relevance: Source for theanine’s glutamate-receptor binding potency: IC₅₀ 24.6 ± 0.9 mM (AMPA), 41.5 ± 7.6 mM (kainate) and 347 ± 47 mM (NMDA strychnine-insensitive glycine site), versus L-glutamic acid at 0.311, 0.537 and 0.011 mM, described by the authors as 80- to 30,000-fold weaker.
Mátyus, R. O., Szikora, Z., Bodó, D., Vargáné Szabó, B., Csupor, É., Csupor, D., & Tóth, B. (2025). Promising, but not completely conclusive: The effect of L-theanine on cognitive performance based on the systematic review and meta-analysis of randomized placebo-controlled clinical trials. Journal of Clinical Medicine, 14(21), 7710. DOI: 10.3390/jcm14217710. PubMed: 41227106. Relevance: PROSPERO CRD42024575122. Five randomized placebo-controlled trials, 148 healthy adults; doses of 50, 100, 200 and 400 mg plus one weight-based arm at 6 mg/kg. Reports a dose-dependent effect on rapid visual information processing, with no significant effect on simple reaction time or on either Stroop condition. Random-effects model; Cochrane Risk of Bias 2.0. Small pooled sample.
National Institutes of Health, Office of Dietary Supplements. (n.d.). Vitamin B6: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/ Relevance: Source for the vitamin B6 RDAs (1.3 mg at 19–50 years; 1.5–1.7 mg at 51 and over), the US tolerable upper intake level of 100 mg/day, the identification of PLP as an active coenzyme form, the statements that phosphorylated forms are dephosphorylated before absorption and that absorption does not differ substantially among supplement forms, and the documented interactions with levodopa and phenytoin.
Pouteau, E., Kabir-Ahmadi, M., Noah, L., Mazur, A., Dye, L., Hellhammer, J., Pickering, G., & Dubray, C. (2018). Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesemia: A randomized, single-blind clinical trial. PLOS ONE, 13(12), e0208454. DOI: 10.1371/journal.pone.0208454. PubMed: 30562392. Relevance: Randomized, investigator-blinded Phase IV trial; 264 adults (modified intention-to-treat) with low serum magnesium and DASS-42 stress scores above 18; magnesium plus pyridoxine or magnesium alone for 8 weeks. Both arms reduced DASS-42 stress scores substantially (44.9% and 42.4%) with no difference between arms; the authors conclude that adding vitamin B6 was not superior to magnesium alone in the full population. In a post hoc subgroup with severe or extremely severe stress (n=162), added by a statistical analysis plan amendment after the blinded database lock, the combination produced 24% greater improvement at Week 8 (p=0.0203). Doses substantially above those in L-Theanine Pro, and pyridoxine rather than P-5-P.
Sebih, F., Rousset, M., Bellahouel, S., Rolland, M., de Jesus Ferreira, M. C., Guiramand, J., Cohen-Solal, C., Barbanel, G., Cens, T., Abouazza, M., Tassou, A., Gratuze, M., Meusnier, C., Charnet, P., Vignes, M., & Rolland, V. (2017). Characterization of L-theanine excitatory actions on hippocampal neurons: Toward the generation of novel N-methyl-D-aspartate receptor modulators based on its backbone. ACS Chemical Neuroscience, 8(8), 1724–1734. DOI: 10.1021/acschemneuro.7b00036. PubMed: 28511005. Relevance: The electrophysiology source for the receptor-mechanism statement. On cultured hippocampal neurons, L-theanine and its derivatives exhibited partial co-agonistic action at NMDA receptors, with no detectable agonist effect at other glutamate receptors. In vitro neuronal culture data.
Synapharm Industrial Synthesis. (2021). Production process for magnesium N-acetyl taurinate (U.S. Patent No. 11,053,194 B2). US Patent and Trademark Office. Relevance: The patent family behind magnesium acetyl taurate. Assignee of record is Synapharm Industrial Synthesis (Belgium); granted claims cover a production process, not the molecule itself. Family members include BE1026955B1 and DK3750873T3.
US Food and Drug Administration. (n.d.). GRAS notice inventory. https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory Relevance: Contains four L-theanine records, three closed with “FDA has no questions” and one pending. Self-affirmed GRAS conclusions do not appear in this inventory and are not FDA determinations.
[Primary evidence: brain delivery, preclinical] Uysal, N., Kizildag, S., Yuce, Z., Guvendi, G., Kandis, S., Koc, B., Karakilic, A., Camsari, U. M., & Ates, M. (2019). Timeline (bioavailability) of magnesium compounds in hours: Which magnesium compound works best? Biological Trace Element Research, 187(1), 128–136. DOI: 10.1007/s12011-018-1351-9. PubMed: 29679349. Relevance: Six groups of 7 Sprague Dawley rats (control plus five magnesium forms); single dose of 400 mg per 70 kg body weight, described by the authors as the recommended daily dose for men; magnesium sulfate given by injection and the other forms orally; behavior assessed at 6 h, blood and tissue sampled at 8 h (2 h for the parenteral comparator).
Magnesium acetyl taurate reached the highest brain tissue magnesium concentration (p<0.05 versus citrate; p<0.0001 versus all other groups) and was the only form for which brain tissue magnesium rose relative to control, while its blood and muscle magnesium levels were comparatively low. Magnesium citrate’s brain tissue level was the next closest. Magnesium malate had the highest area under the curve, acetyl taurate second. Magnesium oxide and citrate showed the lowest overall bioavailability. Magnesium L-threonate was not tested. Animal model, at far more magnesium than a single capsule provides.
van der Pijl, P. C., Chen, L., & Mulder, T. P. J. (2010). Human disposition of L-theanine in tea or aqueous solution. Journal of Functional Foods, 2(4), 239–244. DOI: 10.1016/j.jff.2010.08.001. Relevance: The dedicated human pharmacokinetics study of oral L-theanine (25–100 mg). Lag time approximately 10 minutes, absorption half-life approximately 15 minutes, time to peak concentration approximately 50 minutes, elimination half-life approximately 65 minutes, Cmax 1.0–4.4 mg/L with dose-proportional Cmax and AUC. Not indexed in PubMed.
Yokogoshi, H., Kobayashi, M., Mochizuki, M., & Terashima, T. (1998). Effect of theanine, γ-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochemical Research, 23(5), 667–673. DOI: 10.1023/A:1022490806093. PubMed: 9566605. Relevance: The primary source for the monoamine finding and for the leucine-preferring transport system statement. Intragastric theanine increased serotonin and dopamine concentrations in rat striatum, hypothalamus and hippocampus; dose-dependent striatal dopamine release was demonstrated after direct intrastriatal microinjection. Rodent data, including a direct-brain-administration route.
Source-selection standard: Sources with commercial conflicts are cited with the conflict disclosed. One 2026 systematic review of standalone L-theanine sleep trials was excluded on the separate ground that three of its four authors are employees of a tobacco company, a category of funder we do not cite regardless of finding; its conclusions are directionally consistent with Bulman et al. 2025, which is cited instead.
Evidence note: This guide prioritizes meta-analyses of randomized trials and randomized controlled trials for efficacy-related statements, and identifies preclinical, post hoc and subjective-measure findings as such. Where a result is within-condition rather than versus placebo, limited to a subgroup, or uncorrected for multiple comparisons, that is stated. Not all trials have found benefits; some reported no significant effect, and the nulls are reported alongside the positive findings here.
All human clinical evidence cited for L-theanine covers the 200 mg daily dose delivered by one capsule, except the sleep meta-analysis, whose pooled doses span a wide range and which is labeled accordingly. No human trial of magnesium acetyl taurate has been published at any dose; its brain-delivery evidence is preclinical. No efficacy trial of P-5-P at 2 mg exists; it is included on cofactor rationale. The three-ingredient combination in L-Theanine Pro has not been evaluated in a clinical trial.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.